If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ™ (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the dose of Omvoh™ (mirikizumab-mrkz) be adjusted for renal function?
No dosing adjustments are needed in patients with renal impairment.
Mirikizumab-mrkz is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1
Mild and moderate renal impairment (ie, estimated creatinine clearance by Cockcroft-Gault equation: 30 to 89 mL/min) caused no clinically significant differences in the pharmacokinetics of mirikizumab-mrkz.1
Enclosed Prescribing Information
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: May 30, 2023